You are in: Information > Summary

Summary

The Brussels Pharmaceuticals Conference will be held on the 13 October 2010. This high-level event will provide a unique opportunity for key stakeholders to discuss the current developments in European pharmaceutical policy.

Browse the website now for the latest updates and speaker details.

Speakers include

Marisa Matias MEP

Rapporteur - Counterfeit Medicines

European Parliament

Antonyia Parvanova MEP

Shadow Rapporteur - Pharmacovigilance

European Parliament

Jorgo Chatzimarkakis MEP

Shadow Rapporteur - Information to Patients

European Parliament

Barry Arnold

EU Qualified Person for Pharmacovigilance

AstraZeneca

Martin Fitzgerald

Legal Advisor

European Association of Pharmaceutical Full-Line Wholesalers

More speakers will be confirmed shortly. Please check the website regularly for updates.

Futher Information

This one–day conference aims to reflect on the progress being made in meeting the objective of the European Commission’s Pharmaceutical Package to provide safe, innovative and accessible medicines to European citizens. By bringing together high-level speakers from both the research based and generic pharma Industry, NGO’s and EU Institutions, this Forum Europe conference will assess the relative merits and weaknesses of the regulatory measures proposed and seek to find consensus and agreement on how to move forward.

Topics to be discussed include...

The proposed strengthening of the EU pharmacovigilance system

The proposal concerning Pharmacovigilance sets out the need to strengthen existing legislation on the monitoring of post market drug safety in order to ensure that adverse drug reactions are correctly reported and monitored. This session will address a number of questions including: What measures can be taken to ensure that these recommendations are applied uniformly across member states? What will be the role of the European Medicine Agencies Eudravigilance database? Can lessons be learnt from the United States’ Pharmacovigilance system?

Counterfeit medicines and the European supply chain

As the prevalence of access to counterfeit drugs increases both online and in member states’ legal supply chains, what regulatory measures can be taken to protect European Citizens? What are the roles and responsibilities of the pharmaceutical industry itself in ensuring the traceability of its medicines from production line to patient via wholesaler and pharmacist? Should the rules on Parallel Pharmaceutical Trade be tightened? How can the sale of counterfeit drugs on the internet be curbed?

Information to Patients: ensuring the right balance

One of the most controversial aspects of the Pharmaceutical Package: the proposal concerning information to patients recommends a change in legislation that would allow pharmaceutical companies to provide information directly to the patient for the first time. With the debate currently stalled in parliament, where does the balance lie in terms of improvements in the internal market and consumer privacy and protection?